M Ventures Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
18

- Investments
-
128
- Portfolio
-
58
- Exits
-
22

M Ventures General Information
Description
Founded in 2009, M Ventures is a corporate venture capital arm of Merck KGaA based in Amsterdam, Netherlands. The firm prefers to invest in seed-stage, early-stage, and later-stage companies. The firm seeks to invest in healthcare, information technology, materials, resources, life sciences, oncology, advanced manufacturing, internet of things, artificial intelligence, machine learning, and technology-based sectors.
Contact Information
Website
www.m-ventures.com
Year Founded
2009
Investor Status
Actively Seeking New Investments
Primary Investor Type
Corporate Venture Capital
Other Investor Types
Accelerator/Incubator
Primary Office
- Gustav Mahlerplein 102
- Toyo lto Building, 20th Floor
- 1082 MA Amsterdam
- Netherlands
M Ventures Investments (128)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Biolinq | 27-May-2022 | Later Stage VC | 00000 | Monitoring Equipment | Product In Beta Test | |
0000000 | 30-Mar-2022 | 00000 00000 | 0000 | Other Healthcare Technology Systems | Generating Revenue | 0000000 0000000000000 00.0 |
0000000 | 23-Feb-2022 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | |
000000 00000000000 | 22-Feb-2022 | 0000 00000 | 00.000 | Drug Discovery | Startup | |
000000000 00 | 04-Feb-2022 | 00000 00000 | 0000 | Application Specific Semiconductors | Stealth | |
000000 000000000 | 06-Jan-2022 | 00000 00000 | 00.000 | Diagnostic Equipment | Generating Revenue | 0000000 0000000000000 00.0 |
00000000 000000000 | 29-Dec-2021 | 00000 00000 | 0000 | Electronic Equipment and Instruments | Generating Revenue | |
00000000000 | 01-Dec-2021 | 00000 00000 | Other Healthcare Technology Systems | Generating Revenue | ||
DNA Script | 26-Oct-2021 | Later Stage VC | 00000 | Biotechnology | Generating Revenue | |
iOmx Therapeutics | 05-Oct-2021 | Later Stage VC | 000.00 | Drug Discovery | Pre-Clinical Trials |
M Ventures Exits (22)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Forendo Pharma | 13-Dec-2021 | Merger/Acquisition | 00000 |
00000 000000000000 | 22-Oct-2021 | 000 | 00000 |
00000000 000000000 | 16-Sep-2021 | 000 00 00000000 | |
0000000 000 0 | 10-Feb-2021 | 000 00 00000000 | |
0-0000 00000000000 | 20-Nov-2020 | 0000000 000000 | |
0000000 | 25-Oct-2019 | 000 | 00000 |
0000 0000 000 | 01-Sep-2019 | 000000000 00000000 | |
000000000 | 01-Jan-2019 | 000 00 00000000 | |
Neviah Genomics | 01-Aug-2018 | Out of Business | |
Translate Bio | 28-Jun-2018 | IPO | 00000 |
M Ventures Investments by Industry, Year, and Region
M Ventures Team (79)
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Javier Rodriguez | Chief Financial Officer | Darmstadt, Germany | |||
Hakan Goker Ph.D | Managing Director Biotechnology | 00 | 0 | 0 | Amsterdam, Netherlands |
Christian Patze Ph.D | Investment Principal Technology | 0 | 0 | 0 | Cambridge, MA |
Sarah Luppino Ph.D | Investment Associate Technology | Amsterdam, Netherlands | |||
Therese Liechtenstein Ph.D | Investment Principal Biotechnology | 0 | 0 | 0 | Amsterdam, Netherlands |
M Ventures Co-Investors (302)
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
Novartis Venture Fund | 5 | 0 | 0 |
![]() |
![]() |
Alexandria Venture Investments | 0 | 0 |
![]() |
![]() |
|
Pfizer Ventures | 0 | 0 |
![]() |
![]() |
|
Applied Ventures | 0 | 0 |
![]() |
![]() |
|
IP Group | 0 | 0 |
![]() |
![]() |